VITRECTOMY FOR VITREOUS HEMORRHAGE ASSOCIATED WITH RETINAL VEIN OCCLUSION: Visual Outcomes, Prognostic Factors, and Sequelae.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
24
8
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
To report the outcomes of pars plana vitrectomy for vitreous hemorrhage (VH) associated with retinal vein occlusion and to identify prognostic indicators. Interventional, retrospective consecutive case series between 2015 and 2021. The study included 138 eyes of 138 patients (64 female and 74 male); 81 patients had branch retinal vein occlusion and 57 had central retinal vein occlusion. The mean age was 69.8 years. The mean duration between the diagnosis of VH and surgery was 79.6 ± 115.3 (range, 1-572) days. The mean follow-up was 27.2 months. The logarithm of the minimum angle of resolution visual acuity significantly improved from 1.95 ± 0.72 (Snellen equivalent, 20/1782) to 0.99 ± 0.87 (20/195) at 6 months and to 1.06 ± 0.96 (20/230) at the final visit (both P < 0.001). The visual acuity at 6 months improved by three or more lines in 103 eyes (75%). Postoperative complications during follow-up included recurrent VH in 16 eyes (12%) (of which 8 eyes underwent reoperations), rhegmatogenous retinal detachment in six eyes (4%), and new neovascular glaucoma in three eyes (2%). Worse final visual acuity was significantly associated with older age ( P = 0.007), concurrent neovascular glaucoma ( P < 0.001), central retinal vein occlusion ( P < 0.001), worse preoperative visual acuity ( P < 0.001), postoperative new neovascular glaucoma ( P = 0.021), and postoperative retinal detachment ( P < 0.001). The duration of VH was not associated with visual outcomes ( P = 0.684). Preoperative antivascular endothelial growth factor injections and tamponade did not prevent postoperative recurrent VH. Pars plana vitrectomy is effective for VH associated with retinal vein occlusion, regardless of the duration of hemorrhage. However, pre-existing risk factors and postoperative sequelae may limit visual recovery.
Identifiants
pubmed: 37294906
doi: 10.1097/IAE.0000000000003839
pii: 00006982-990000000-00386
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1506-1513Références
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313–319.e1.
Newman-Casey PA, Stem M, Talwar N, et al. Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan. Ophthalmology 2014;121:1939–1948.
Johnston RL, Brucker AJ, Steinmann W, et al. Risk factors of branch retinal vein occlusion. Arch Ophthalmol 1985;103:1831–1832.
Zhou JQ, Xu L, Wang S, et al. The 10-year incidence and risk factors of retinal vein occlusion. Ophthalmology 2013;120:803–808.
Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion. Retina 2013;33:901–910.
Yeh S, Kim SJ, Ho AC, et al. Therapies for macular edema associated with Central retinal vein occlusion. Ophthalmology 2015;122:769–778.
Yeshaya A, Treister G. Pars plana vitrectomy for vitreous hemorrhage and retinal vein occlusion. Ann Ophthalmol 1983;15:615–617.
Chatziralli IP, Jaulim A, Peponis VG, et al. Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol 2014;29:85–107.
Smiddy WE, Isernhagen RD, Michels RG, et al. Vitrectomy for nondiabetic vitreous hemorrhage. Retina 1988;8:88–95.
Amirikia A, Scott IU, Murray TG, et al. Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion. Ophthalmology 2001;108:372–375.
Chuang L-H, Wang N-K, Chen Y-P, et al. Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage. Retina 2013;33:798–802.
Govetto A, Lalane RA, Sarraf D, et al. Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol 2017;175:99–113.
LO WR, KIM SJ, AABERG TM, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina 2009;29:926–931.
Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy. JAMA 2020;324:2383–2395.
Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. Ophthalmology 1983;90:522–530.
Mason JO, Colagross CT, Vail R. Diabetic vitrectomy: risks, prognosis, future trends. Curr Opin Ophthalmol 2006;17:281–285.
Yau GL, Silva PS, Arrigg PG, Sun JK. Postoperative complications of pars plana vitrectomy for diabetic retinal disease. Semin Ophthalmol 2018;33:126–133.
Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 1984;91:1485–1489.
Khuthaila MK, Hsu J, Chiang A, et al. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol 2013;155:757–763.e2.
Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118:2218–2226.
Yang C-M, Yeh P-T, Yang C-H. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710–715.
Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients A randomized clinical trial. Ophthalmology 2009;116:1943–1948.
Rush RB, Velazquez JC, Rosales CR, Rush SW. Gas tamponade for the prevention of postoperative vitreous hemorrhaging after diabetic vitrectomy: a randomized clinical trial. Am J Ophthalmol 2022;242:173–180.
Yan H, Cui J, Lu Y, et al. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy. Curr Eye Res 2010;35:308–313.
Magargal LE, Brown GC, Augsburger JJ, Parrish RK. Neovascular glaucoma following central retinal vein obstruction. Ophthalmology 1981;88:1095–1101.
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434–1444.